FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use
Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:CHRAC1-SNTG1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: CHRAC1-SNTG1
FusionPDB ID: 16637
FusionGDB2.0 ID: 16637
HgeneTgene
Gene symbol

CHRAC1

SNTG1

Gene ID

54108

54212

Gene namechromatin accessibility complex subunit 1syntrophin gamma 1
SynonymsCHARC1|CHARC15|CHRAC-1|CHRAC-15|CHRAC15|YCL1G1SYN|SYN4
Cytomap

8q24.3

8q11.21

Type of geneprotein-codingprotein-coding
Descriptionchromatin accessibility complex protein 1DNA polymerase epsilon subunit p15chromatin accessibility complex 1chromatin accessibility complex 15 kDa proteinhistone-fold protein CHRAC15gamma-1-syntrophingamma1-syntrophinsyntrophin 4
Modification date2020031320200313
UniProtAcc

Q9NRG0

Main function of 5'-partner protein: FUNCTION: Forms a complex with DNA polymerase epsilon subunit POLE3 and binds naked DNA, which is then incorporated into chromatin, aided by the nucleosome remodeling activity of ISWI/SNF2H and ACF1.		.
Ensembl transtripts involved in fusion geneENST idsENST00000220913, ENST00000519533, 
ENST00000520697, ENST00000276467, 
ENST00000517473, ENST00000518864, 
ENST00000522124, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score5 X 5 X 3=7511 X 11 X 6=726
# samples 512
** MAII scorelog2(5/75*10)=-0.584962500721156
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0		log2(12/726*10)=-2.59693514238723
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: CHRAC1 [Title/Abstract] AND SNTG1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: CHRAC1 [Title/Abstract] AND SNTG1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)CHRAC1(141521745)-SNTG1(51351103), # samples:2
Anticipated loss of major functional domain due to fusion event.CHRAC1-SNTG1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CHRAC1-SNTG1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:141521745/chr8:51351103)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across CHRAC1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across SNTG1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)		BP loci
(transcript)		Predicted start
(transcript)		Predicted stop
(transcript)		Seq length
(amino acids)
ENST00000220913CHRAC1chr8141521745+ENST00000518864SNTG1chr851351103+17413492021740513
ENST00000220913CHRAC1chr8141521745+ENST00000522124SNTG1chr851351103+30303492021740512
ENST00000220913CHRAC1chr8141521745+ENST00000517473SNTG1chr851351103+16683492021629475
ENST00000220913CHRAC1chr8141521745+ENST00000276467SNTG1chr851351103+16663492021629475
ENST00000519533CHRAC1chr8141521745+ENST00000518864SNTG1chr851351103+17283361891727512
ENST00000519533CHRAC1chr8141521745+ENST00000522124SNTG1chr851351103+30173361891727512
ENST00000519533CHRAC1chr8141521745+ENST00000517473SNTG1chr851351103+16553361891616475
ENST00000519533CHRAC1chr8141521745+ENST00000276467SNTG1chr851351103+16533361891616475

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000220913ENST00000518864CHRAC1chr8141521745+SNTG1chr851351103+0.0057128070.9942872
ENST00000220913ENST00000522124CHRAC1chr8141521745+SNTG1chr851351103+0.0006133030.99938667
ENST00000220913ENST00000517473CHRAC1chr8141521745+SNTG1chr851351103+0.0057357480.9942642
ENST00000220913ENST00000276467CHRAC1chr8141521745+SNTG1chr851351103+0.0057286840.9942713
ENST00000519533ENST00000518864CHRAC1chr8141521745+SNTG1chr851351103+0.005606330.9943937
ENST00000519533ENST00000522124CHRAC1chr8141521745+SNTG1chr851351103+0.0006032610.9993967
ENST00000519533ENST00000517473CHRAC1chr8141521745+SNTG1chr851351103+0.0057544050.9942456
ENST00000519533ENST00000276467CHRAC1chr8141521745+SNTG1chr851351103+0.0057464040.9942536

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CHRAC1-SNTG1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
CHRAC1chr8141521745SNTG1chr85135110333649INQEALVLTAKATERTVTIRRQTVGG
CHRAC1chr8141521745SNTG1chr85135110334949INQEALVLTAKATERTVTIRRQTVGG

Top

Potential FusionNeoAntigen Information of CHRAC1-SNTG1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CHRAC1-SNTG1_141521745_51351103.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CHRAC1-SNTG1chr8141521745chr851351103349HLA-B15:16KATERTVTI0.99360.78221019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-B52:01KATERTVTI0.59350.94411019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-B13:02KATERTVTI0.47360.51841019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-A31:06ATERTVTIRR0.73230.62731121
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C15:04KATERTVTI0.99980.84231019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C15:06KATERTVTI0.99970.83641019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C03:07KATERTVTI0.99950.96681019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C03:08KATERTVTI0.99810.87741019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C03:19KATERTVTI0.99720.97971019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C04:06KATERTVTI0.99550.85471019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C02:06KATERTVTI0.97990.90371019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C01:17KATERTVTI0.9630.88611019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C12:12KATERTVTI0.96250.85451019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C12:04TAKATERTV0.95110.9807817
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C08:04KATERTVTI0.94610.91891019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C08:13KATERTVTI0.94610.91891019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C03:14KATERTVTI0.94310.95621019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C06:03TAKATERTV0.94270.9834817
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C06:03KATERTVTI0.93920.9731019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C12:04KATERTVTI0.93570.96741019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-B51:07TAKATERTV0.92410.8622817
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C12:12TAKATERTV0.92410.9065817
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C08:03KATERTVTI0.73860.96081019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C01:30KATERTVTI0.61640.8991019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-A31:01ATERTVTIRR0.88750.6881121
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C15:09KATERTVTI0.99980.84231019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C15:05KATERTVTI0.99970.8121019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C15:02KATERTVTI0.99970.76231019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C06:06KATERTVTI0.99780.97221019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C03:17KATERTVTI0.99740.94911019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C03:67KATERTVTI0.99720.97451019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C03:05KATERTVTI0.99670.91261019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C16:02KATERTVTI0.99660.97951019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C03:04KATERTVTI0.99530.98251019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C03:03KATERTVTI0.99530.98251019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-A32:01KATERTVTI0.98980.84421019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C07:04KATERTVTI0.98450.921019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C16:01KATERTVTI0.9790.95111019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C01:03KATERTVTI0.97480.90261019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C06:08KATERTVTI0.97210.96211019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C02:02KATERTVTI0.96840.9381019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C02:10KATERTVTI0.96840.9381019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C01:02KATERTVTI0.96830.87931019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C03:06KATERTVTI0.96830.98431019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C06:02KATERTVTI0.95560.96551019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C06:17KATERTVTI0.95560.96551019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C16:04KATERTVTI0.95410.92881019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C12:03KATERTVTI0.93670.9241019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C12:03TAKATERTV0.88040.9595817
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C16:04TAKATERTV0.87190.9444817
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C12:02KATERTVTI0.8010.88541019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C17:01KATERTVTI0.77690.87821019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-C08:01KATERTVTI0.73860.96081019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-B35:13KATERTVTI0.64790.83921019
CHRAC1-SNTG1chr8141521745chr851351103349HLA-B07:13KATERTVTI0.55830.72641019

Top

Potential FusionNeoAntigen Information of CHRAC1-SNTG1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CHRAC1-SNTG1_141521745_51351103.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0801NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0801QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0803QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0803NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0805NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0805QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0806NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0806QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0806INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0808QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0810QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0810NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0810INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0811QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0812QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0812NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0812INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0814QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0814NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0816NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0816QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0818NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0818QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0822QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0822NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0822INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0823QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0823NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0826NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0826QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0827QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0827NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0829NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0829QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0829INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0833QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0833NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0835QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0835NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0836QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0836NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0838QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0838NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0839NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0839QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0840NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-0840QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1154QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1154NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1303NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1303QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1303INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-13101NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-13101QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1310NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1310QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1312NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1312QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1312INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1313QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1313NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1321QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1321NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1321INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1330QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1330NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1330INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1332QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1333QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1333NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1338QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1348QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1349NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1349QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1355NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1355QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1355INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1358QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1358NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1358INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1365QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1366NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1366QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1366INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1381NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1381QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1381INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1388NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1388QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1388INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1389NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1389QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1389INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1390NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1390QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1390INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1394QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1394NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1394INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1395NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1395QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1395INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1413QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1413NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1422QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1422NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1425QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1425NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1433QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1433NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1453QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1453NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1462NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1463QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1463NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1465QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1465NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1469QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1469NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1473NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1473QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1473INQEALVLTAKATER015
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1474QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1474NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1478QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1478NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1485QEALVLTAKATERTV217
CHRAC1-SNTG1chr8141521745chr851351103349DRB1-1485NQEALVLTAKATERT116
CHRAC1-SNTG1chr8141521745chr851351103349DRB5-0106EALVLTAKATERTVT318
CHRAC1-SNTG1chr8141521745chr851351103349DRB5-0205EALVLTAKATERTVT318

Top

Fusion breakpoint peptide structures of CHRAC1-SNTG1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
10106VLTAKATERTVTIRCHRAC1SNTG1chr8141521745chr851351103349

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CHRAC1-SNTG1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN10106VLTAKATERTVTIR-7.9962-8.1096
HLA-B14:023BVN10106VLTAKATERTVTIR-5.70842-6.74372
HLA-B52:013W3910106VLTAKATERTVTIR-6.83737-6.95077
HLA-B52:013W3910106VLTAKATERTVTIR-4.4836-5.5189
HLA-A11:014UQ210106VLTAKATERTVTIR-10.0067-10.1201
HLA-A11:014UQ210106VLTAKATERTVTIR-9.03915-10.0745
HLA-A24:025HGA10106VLTAKATERTVTIR-6.56204-6.67544
HLA-A24:025HGA10106VLTAKATERTVTIR-5.42271-6.45801
HLA-B44:053DX810106VLTAKATERTVTIR-7.85648-8.89178
HLA-B44:053DX810106VLTAKATERTVTIR-5.3978-5.5112
HLA-B35:011A1N10106VLTAKATERTVTIR-6.27422-6.38762
HLA-B35:011A1N10106VLTAKATERTVTIR-5.27424-6.30954
HLA-A02:016TDR10106VLTAKATERTVTIR-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of CHRAC1-SNTG1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
CHRAC1-SNTG1chr8141521745chr8513511031019KATERTVTIAAGGCCACGGAAAGAACGGTGACCATC
CHRAC1-SNTG1chr8141521745chr8513511031121ATERTVTIRRGCCACGGAAAGAACGGTGACCATCAGAAGA
CHRAC1-SNTG1chr8141521745chr851351103817TAKATERTVACGGCCAAGGCCACGGAAAGAACGGTG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
CHRAC1-SNTG1chr8141521745chr851351103015INQEALVLTAKATERATCAACCAGGAGGCGTTGGTGCTCACGGCCAAGGCCACGGAAAGA
CHRAC1-SNTG1chr8141521745chr851351103116NQEALVLTAKATERTAACCAGGAGGCGTTGGTGCTCACGGCCAAGGCCACGGAAAGAACG
CHRAC1-SNTG1chr8141521745chr851351103217QEALVLTAKATERTVCAGGAGGCGTTGGTGCTCACGGCCAAGGCCACGGAAAGAACGGTG
CHRAC1-SNTG1chr8141521745chr851351103318EALVLTAKATERTVTGAGGCGTTGGTGCTCACGGCCAAGGCCACGGAAAGAACGGTGACC

Top

Information of the samples that have these potential fusion neoantigens of CHRAC1-SNTG1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BLCACHRAC1-SNTG1chr8141521745ENST00000220913chr851351103ENST00000276467TCGA-G2-A3VY-01A

Top

Potential target of CAR-T therapy development for CHRAC1-SNTG1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to CHRAC1-SNTG1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to CHRAC1-SNTG1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource